Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle

被引:43
|
作者
Seelig, AS [1 ]
Al-Hasani, S [1 ]
Katalinic, A [1 ]
Schöpper, B [1 ]
Sturm, R [1 ]
Diedrich, K [1 ]
Ludwig, M [1 ]
机构
[1] Univ Clin Hosp, Dept Gynecol & Obstet, D-23538 Lubeck, Germany
关键词
cetrorelix; cryopreservation; GnRH agonist; GnRH antagonist; open freezing system;
D O I
10.1016/S0015-0282(01)03008-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the pregnancy rates of frozen-thawed 2-pronucleate (2PN) oocytes obtained either in a long protocol or in an antagonist protocol and ovarian stimulation with either human menopausal gonadotropin (hMG) or recombinant follicular stimulating hormone (recFSH). Design: Retrospective data analysis. Setting: Academic infertility center. Patient(s): Three hundred forty-two infertile couples who under-went a transfer of cryopreserved 2PN oocytes. Intervention(s): hMG (n = 194) or recFSH (n = 92) in a long protocol or hMG (n = 16) or recFSH (n = 40) stimulation under pituitary suppression with the GnRH antagonist Cetrotide was used. The 2PN oocytes were transferred after endometrial preparation using E, valerate and vaginal progesterone (Crinone 8% vaginal gel). Main Outcome Measure(s): Implantation, pregnancy, and abortion rates. Result(s): Implantation rates in the freeze-thaw cycles were 5.6% (hMG) and 3.8% (recFSH) with 2PN oocytes from the long protocol and 7% from the antagonist cycles, irrespective of whether hMG or reeFSH was used. Pregnancy rates were similar independent of whether they resulted from the long-protocol cycles with hMG (15.4%) and recFSH (13.1%) or from the antagonist protocol cycles with hMG (25.0%) and recFSH ( 17.5%. Conclusion(s): The potential to implant is independent of the gonadotropin-releasing hormone analogue and gonadotropin chosen for the collection cycle when previously cryopreserved 2PN oocytes were replaced after thawing in the cleavage stage. (Fertil Steril(R) 2002:77:472-5. (C)2002 by American Society for Reproductive Medicine.).
引用
收藏
页码:472 / 475
页数:4
相关论文
共 50 条
  • [1] Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the control ovarian hyperstimulation cycles.
    Ma, C.
    Qiao, J.
    Liu, P.
    Wang, C.
    FERTILITY AND STERILITY, 2006, 86 : S163 - S163
  • [2] Gonadoliberin (Gonadotropin-Releasing Hormone), Its Agonists and Antagonists
    Holicka, Martina
    Vyslouzil, Jakub
    Kubova, Katerina
    Muselik, Jan
    Vetchy, David
    CHEMICKE LISTY, 2021, 115 (10): : 516 - 523
  • [3] Gonadotropin releasing hormone antagonists and cryopreservation outcome: A review
    Nikolettos N.
    Asimakopoulos B.
    Simopoulou M.
    Al-Hasani S.
    Diedrich K.
    Archives of Gynecology and Obstetrics, 2004, 270 (2) : 69 - 73
  • [4] Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better?
    Blumenfeld, Z
    FERTILITY AND STERILITY, 2001, 76 (03) : 443 - 444
  • [5] GONADOTROPIN-RELEASING HORMONE - PHYSIOLOGICAL AND THERAPEUTIC ASPECTS, AGONISTS AND ANTAGONISTS
    SANTEN, RJ
    BOURGUIGNON, JP
    HORMONE RESEARCH, 1987, 28 (2-4) : 88 - 103
  • [6] Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function
    DiLuigi, Andrea J.
    Nulsen, John C.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007, 19 (03) : 258 - 265
  • [7] EFFECTS OF GONADOTROPIN-RELEASING HORMONE AGONISTS AND ANTAGONISTS ON REPRODUCTIVE FUNCTIONS
    RIVIER, C
    VALE, W
    RIVIER, J
    JOURNAL OF MEDICINAL CHEMISTRY, 1983, 26 (11) : 1545 - 1550
  • [8] Gonadotropin-releasing hormone: An update review of the antagonists versus agonists
    Van Poppel, Hein
    Klotz, Laurence
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (07) : 594 - 601
  • [9] Gonadotropin-releasing hormone antagonists
    Herbst, KL
    CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (06) : 660 - 666
  • [10] RADIOLIGAND ASSAY FOR GONADOTROPIN-RELEASING HORMONE - RELATIVE POTENCIES OF AGONISTS AND ANTAGONISTS
    PERRIN, MH
    RIVIER, JE
    VALE, WW
    ENDOCRINOLOGY, 1980, 106 (04) : 1289 - 1296